European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis

Roche presents new Alzheimer’s research at AAIC 2025

Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease

INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease

Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study

Muna Therapeutics and GSK to accelerate development of novel treatments for Alzheimer’s disease

GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg

Roche's Elecsys Amyloid Plasma Panel granted FDA breakthrough device designation to enable a timely diagnosis of Alzheimer’s disease

The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.

Diadem announces publication of peer-reviewed article on Alzheimer’s disease

It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023